<--- Back to Details
First PageDocument Content
Pharmacology / S. E. Massengill Company / Beecham / Smith /  Kline & French / Elixir sulfanilamide / GlaxoWellcome / Ranitidine / Pharmaceutical industry / King Pharmaceuticals / GlaxoSmithKline / Medicine / Health
Date: 2009-08-28 10:16:34
Pharmacology
S. E. Massengill Company
Beecham
Smith
Kline & French
Elixir sulfanilamide
GlaxoWellcome
Ranitidine
Pharmaceutical industry
King Pharmaceuticals
GlaxoSmithKline
Medicine
Health

Add to Reading List

Source URL: pubs.acs.org

Download Document from Source Website

File Size: 71,82 KB

Share Document on Facebook

Similar Documents

S&P/TSX 60 Index / S&P/TSX Composite Index / Valeant Pharmaceuticals / Carl Icahn / Companies listed on the New York Stock Exchange

M&A and Contested Solicitation Assignments © 2016 D.F. King & Co., Inc. | Confidential – Not For Distribution Mergers •

DocID: 1oYLi - View Document

Patent law / Patentable subject matter / Inventive step and non-obviousness / Patent / Printed matter / Novelty

2010 PATENTLY-O PATENT LAW JOURNAL An Initial Comment on King Pharmaceuticals: The Printed Matter Doctrine as a Structural Doctrine and Its Implications for Prometheus Laboratories1 By Kevin Emerson Collins2

DocID: 1kS08 - View Document

Federal assistance in the United States / Presidency of Lyndon B. Johnson / Medical informatics / Pharmaceuticals policy / Medicare / Medicaid / Disease management / Evidence-based medicine / Pharmacy benefit management / Health / Healthcare reform in the United States / Medicine

Microsoft PowerPoint - Luncheon - Ruben King-Shaw v.2

DocID: 14BXi - View Document

Basketball / King Abdullah Cup

Venture Capital Funding Quarterly Biotechnology • Pharmaceuticals Medical Devices 4th Quarter, 2013 – North America Publisher VentureDeal

DocID: RQPt - View Document

Basketball / King Abdullah Cup / ABC Under-18 Championship for Women

Venture Capital Funding Quarterly Biotechnology • Pharmaceuticals Medical Devices 3rd Quarter, 2014 – North America Publisher VentureDeal

DocID: ROga - View Document